Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06682793
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:20.988140+00:00
Published At
2025-09-09T00:00:00+00:00
Record Updated At
2025-09-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Solid Tumor, Adult", "Colorectal Cancer", "Non-Small Cell Lung", "NSCLC (Non-small Cell Lung Cancer)", "Cancer", "Colon Cancer", "Rectal Cancer", "Lung Cancer", "CRC", "Head and Neck Squamous Cell Cancer", "HNSCC", "Renal Cell Carcinoma", "RCC", "Kidney Cancer", "Triple Negative Breast Cancer", "TNBC", "Colorectal Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-09-09"
protocolSection.identificationModule.nctId
"NCT06682793"
protocolSection.identificationModule.officialTitle
"A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod\u2122 CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Solid Tumor, Adult (protocolSection.conditionsModule.conditions)
  • Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • Non-Small Cell Lung (protocolSection.conditionsModule.conditions)
  • NSCLC (Non-small Cell Lung Cancer) (protocolSection.conditionsModule.conditions)
  • Cancer (protocolSection.conditionsModule.conditions)
  • Colon Cancer (protocolSection.conditionsModule.conditions)
  • Rectal Cancer (protocolSection.conditionsModule.conditions)
  • Lung Cancer (protocolSection.conditionsModule.conditions)
  • CRC (protocolSection.conditionsModule.conditions)
  • Head and Neck Squamous Cell Cancer (protocolSection.conditionsModule.conditions)
  • HNSCC (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • RCC (protocolSection.conditionsModule.conditions)
  • Kidney Cancer (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • TNBC (protocolSection.conditionsModule.conditions)
  • Colorectal Adenocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.